OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)
South Korea · Delayed Price · Currency is KRW 5,720.00
+230.00 (4.19%)
At close: Jun 9, 2026
OPTUS Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 91,625 | 87,161 | 81,905 | 72,426 | 58,658 | 57,316 |
Other Revenue | - | - | -0 | -0 | - | - |
| 91,625 | 87,161 | 81,905 | 72,426 | 58,658 | 57,316 | |
Revenue Growth (YoY) | 11.80% | 6.42% | 13.09% | 23.47% | 2.34% | -5.77% |
Cost of Revenue | 40,873 | 39,037 | 37,277 | 31,072 | 27,041 | 24,821 |
Gross Profit | 50,752 | 48,125 | 44,628 | 41,354 | 31,617 | 32,495 |
Selling, General & Admin | 36,366 | 35,846 | 32,846 | 30,623 | 24,138 | 20,589 |
Research & Development | 1,737 | 1,731 | 1,883 | 1,384 | 1,343 | 1,110 |
Other Operating Expenses | 222.9 | 234.12 | 260.69 | 164.19 | 184.49 | 110.92 |
Operating Expenses | 39,894 | 39,249 | 36,119 | 33,168 | 26,368 | 22,023 |
Operating Income | 10,859 | 8,875 | 8,509 | 8,187 | 5,249 | 10,472 |
Interest Expense | -68.02 | -69.34 | -97.24 | -124.4 | -85.89 | -8.88 |
Interest & Investment Income | 1,094 | 1,328 | 2,373 | 2,296 | 1,401 | 846.43 |
Currency Exchange Gain (Loss) | 141.58 | 216.69 | 84.8 | 3.33 | 12.17 | 127.54 |
Other Non Operating Income (Expenses) | 343.42 | 281.91 | -469.62 | 11.79 | 21.69 | -36.76 |
EBT Excluding Unusual Items | 12,369 | 10,633 | 10,400 | 10,374 | 6,598 | 11,400 |
Gain (Loss) on Sale of Investments | 50.99 | 16.32 | 1,242 | 1,967 | 73.39 | - |
Gain (Loss) on Sale of Assets | 1,922 | 1,939 | 441.87 | 629.3 | 878.29 | 44.24 |
Asset Writedown | -1,536 | -1,536 | - | - | -721.2 | -964.98 |
Pretax Income | 12,807 | 11,052 | 12,084 | 12,970 | 6,828 | 10,479 |
Income Tax Expense | 110.81 | -305.86 | 1,776 | 2,210 | 1,816 | 587.88 |
Net Income | 12,696 | 11,358 | 10,308 | 10,760 | 5,012 | 9,892 |
Net Income to Common | 12,696 | 11,358 | 10,308 | 10,760 | 5,012 | 9,892 |
Net Income Growth | 39.82% | 10.18% | -4.20% | 114.69% | -49.33% | -31.33% |
Shares Outstanding (Basic) | 16 | 16 | 15 | 15 | 16 | 16 |
Shares Outstanding (Diluted) | 16 | 16 | 15 | 15 | 16 | 16 |
Shares Change (YoY) | 4.23% | 1.78% | 0.48% | -4.18% | -1.07% | -0.62% |
EPS (Basic) | 798.41 | 731.46 | 675.00 | 708.00 | 316.00 | 617.00 |
EPS (Diluted) | 796.92 | 730.00 | 675.00 | 708.00 | 316.00 | 617.00 |
EPS Growth | 34.03% | 8.15% | -4.66% | 124.05% | -48.78% | -30.91% |
Free Cash Flow | -36,768 | -28,290 | -2,903 | 9,109 | -3,955 | -3,557 |
Free Cash Flow Per Share | -2309.98 | -1820.03 | -190.11 | 599.36 | -249.37 | -221.87 |
Gross Margin | 55.39% | 55.21% | 54.49% | 57.10% | 53.90% | 56.69% |
Operating Margin | 11.85% | 10.18% | 10.39% | 11.30% | 8.95% | 18.27% |
Profit Margin | 13.86% | 13.03% | 12.59% | 14.86% | 8.54% | 17.26% |
Free Cash Flow Margin | -40.13% | -32.46% | -3.55% | 12.58% | -6.74% | -6.21% |
EBITDA | 15,748 | 13,583 | 12,486 | 12,424 | 8,712 | 12,895 |
EBITDA Margin | 17.19% | 15.58% | 15.24% | 17.15% | 14.85% | 22.50% |
D&A For EBITDA | 4,890 | 4,708 | 3,977 | 4,238 | 3,463 | 2,423 |
EBIT | 10,859 | 8,875 | 8,509 | 8,187 | 5,249 | 10,472 |
EBIT Margin | 11.85% | 10.18% | 10.39% | 11.30% | 8.95% | 18.27% |
Effective Tax Rate | 0.86% | - | 14.69% | 17.04% | 26.60% | 5.61% |
Advertising Expenses | - | 1,033 | 2,032 | 1,515 | 364.81 | 100.36 |